Adverse Effects of Combined Tyrosine Kinase Inhibitors

被引：0
|
作者：
Lu, Shun [1 ]
Li, Ziming [1 ]
机构：
[1] Shanghai Jiao Tong Univ, Shanghai Chest Hosp, Shanghai Lung Canc Ctr, Shanghai, Peoples R China
来源：
JOURNAL OF THORACIC ONCOLOGY | 2020年 / 15卷 / 11期
关键词：
INTERSTITIAL LUNG-DISEASE; CANCER; C797S; GEFITINIB; T790M;
D O I：
10.1016/j.jtho.2020.07.016
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：E182 / E183
页数：2
相关论文
共 50 条
  • [31] Tyrosine kinase inhibitors: the role of pharmacokinetics and pharmacogenetics
    Sarah, Allegra
    Dondi, Emma
    De Francia, Silvia
    EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY, 2023, 19 (11) : 733 - 739
  • [32] Small molecule tyrosine kinase inhibitors in glioblastoma
    Kim, Gayoung
    Ko, Young Tag
    ARCHIVES OF PHARMACAL RESEARCH, 2020, 43 (04) : 385 - 394
  • [33] Protein tyrosine kinase inhibitors in cancer therapy
    Boutayeb, S.
    Zakkouri, F. Z.
    Aitelhaj, M.
    Mesmoudi, M.
    Boutayeb, A.
    Boutayeb, W.
    Mrabti, H.
    Errihani, H.
    PATHOLOGIE BIOLOGIE, 2012, 60 (04): : 229 - 233
  • [34] Differential Effects of Tyrosine Kinase Inhibitors on Normal and Oncogenic EGFR Signaling and Downstream Effectors
    Kim, Youngjoo
    Apetri, Mihaela
    Luo, BeiBei
    Settleman, Jeffrey E.
    Anderson, Karen S.
    MOLECULAR CANCER RESEARCH, 2015, 13 (04) : 765 - 774
  • [35] Comparison of autophagy inducibility in various tyrosine kinase inhibitors and their enhanced cytotoxicity via inhibition of autophagy in cancer cells in combined treatment with azithromycin
    Tanaka, Hideki
    Hino, Hirotsugu
    Moriya, Shota
    Kazama, Hiromi
    Miyazaki, Masaya
    Takano, Naoharu
    Hiramoto, Masaki
    Tsukahara, Kiyoaki
    Miyazawa, Keisuke
    BIOCHEMISTRY AND BIOPHYSICS REPORTS, 2020, 22
  • [36] Clinical characteristics and outcomes of tyrosine kinase inhibitor-related lower GI adverse effects
    Cynthia Liu
    Rajan Amin
    Malek Shatila
    Nicholas Short
    Mehmet Altan
    Amishi Shah
    Omar Alhalabi
    Pablo Okhuysen
    Anusha S. Thomas
    Yinghong Wang
    Journal of Cancer Research and Clinical Oncology, 2023, 149 : 3965 - 3976
  • [37] Protein tyrosine kinase signaling diversity and susceptibility to targeted kinase inhibitors
    Alaoui-Jamali, M. A.
    BIOMEDICINE & PHARMACOTHERAPY, 2006, 60 (09) : 629 - 632
  • [38] Clinical characteristics and outcomes of tyrosine kinase inhibitor-related lower GI adverse effects
    Liu, Cynthia
    Amin, Rajan
    Shatila, Malek
    Short, Nicholas
    Altan, Mehmet
    Shah, Amishi
    Alhalabi, Omar
    Okhuysen, Pablo
    Thomas, Anusha S.
    Wang, Yinghong
    JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2023, 149 (07) : 3965 - 3976
  • [39] Synergistic anticancer effects of combined γ-tocotrienol with statin or receptor tyrosine kinase inhibitor treatment
    Sylvester, Paul W.
    GENES AND NUTRITION, 2012, 7 (01) : 63 - 74
  • [40] Uncommon EGFR mutations in lung adenocarcinoma: features and response to tyrosine kinase inhibitors
    Brindel, Aurelien
    Althakfi, Wajd
    Barritault, Marc
    Watkin, Emmanuel
    Maury, Jean-Michel
    Bringuier, Pierre-Paul
    Girard, Nicolas
    Brevet, Marie
    JOURNAL OF THORACIC DISEASE, 2020, 12 (09) : 4643 - +
12345